Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis

被引:43
作者
de Carvalho, M
Scotto, M
Lopes, A
Swash, M [1 ]
机构
[1] Univ London Queen Mary Coll, Royal London Hosp, Dept Neurol, London E1 1BB, England
[2] Univ London Queen Mary Coll, Queens Mary Sch Med, London E1 1BB, England
[3] Univ Nova Lisboa, Inst Mol Med, Fac Med,Dept Neurol,Hosp Sant Maria, Ctr Estudos Egas Moniz,EMG Lab, P-1200 Lisbon, Portugal
[4] Univ Aveiro, Dept Math, P-3800 Aveiro, Portugal
[5] Hosp Med Rehabil, Tochoa, Portugal
关键词
amyotrophic lateral sclerosis; compound muscle action potential; disease progression; muscle strength; neurophysiological index;
D O I
10.1002/mus.10469
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is a need for a sensitive neurophysiological measure of disease progression in following the course of patients with amyotrophic lateral sclerosis (ALS). We studied two groups of nine ALS patients, one with slow progression (Group A) and the other with rapid progression (Group B). We evaluated muscle strength scores using the Medical Research Council (MRC) scale in limb and trunk muscles, forced vital capacity (FVC), and ALS functional rating scale (ALS-FRS) scores. Maximal voluntary isometric contraction (MVIC) of the abductor digiti minimi muscle (ADM) was measured, using a digital device. We also measured M-wave amplitude and area in the ADM, and the distal motor latency and F-wave frequency in the ulnar nerve; from these data, the neurophysiological index (NI) was calculated, as described previously. In both groups, the NI was the most sensitive measure of change, with the smallest coefficient of variation. We conclude that the NI, which requires no special technology and no new clinical or technical skills to use, is sensitive to change, and therefore may be useful in clinical trials, as well as in a clinical setting.
引用
收藏
页码:630 / 633
页数:4
相关论文
共 17 条
[1]  
Armon C, 1997, MUSCLE NERVE, V20, P499, DOI 10.1002/(SICI)1097-4598(199704)20:4<499::AID-MUS14>3.0.CO
[2]  
2-U
[3]   Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials [J].
Armon, C ;
Moses, D .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 160 :S37-S41
[4]  
Armon C, 2000, MUSCLE NERVE, V23, P874, DOI 10.1002/(SICI)1097-4598(200006)23:6<874::AID-MUS5>3.0.CO
[5]  
2-U
[6]   MOTOR UNIT NUMBER ESTIMATION, ISOMETRIC STRENGTH, AND ELECTROMYOGRAPHIC MEASURES IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BROMBERG, MB ;
FORSHEW, DA ;
NAU, KL ;
BROMBERG, J ;
SIMMONS, Z ;
FRIES, TJ .
MUSCLE & NERVE, 1993, 16 (11) :1213-1219
[7]   Electrophysiologic endpoint measures in a multicenter ALS drug trial [J].
Bromberg, MB ;
Fries, TJ ;
Forshew, DA ;
Tandan, R .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 184 (01) :51-55
[8]   El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis [J].
Brooks, BR ;
Miller, RG ;
Swash, M ;
Munsat, TL .
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05) :293-299
[9]  
Cedarbaum J.M., 1997, J NEUROL SCI S1, V152, P1
[10]   F-waves and the corticospinal lesion in amyotrophic lateral sclerosis [J].
de Carvalho, M ;
Scotto, M ;
Lopes, A ;
Swash, M .
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2002, 3 (03) :131-136